Volume 4.34 | Sep 9

Cancer Stem Cell News 4.34 September 9, 2014
Cancer Stem Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   CSCN on Twitter
 
TOP STORY
Erosion of the Chronic Myeloid Leukemia Stem Cell Pool by PPARγ Agonists
Scientists showed that the residual chronic myeloid leukemia (CML) leukemia stem cells (LSC) pool can be gradually purged by the glitazones, antidiabetic drugs that are agonists of peroxisome proliferator-activated receptor-γ (PPARγ). They found that activation of PPARγ by the glitazones decreases expression of STAT5 and its downstream targets HIF2α5 and CITED26, which are key guardians of the quiescence and stemness of CML LSCs. [Nature] Abstract
[Watch the Video] Detect Cancer Stem Cells with ALDEFLUOR™.
 
PUBLICATIONS (Ranked by impact factor of the journal)
The Mitotic Kinesin KIF11 Is a Driver of Invasion, Proliferation, and Self-Renewal in Glioblastoma
Inhibition of KIF11 with a highly specific small-molecule inhibitor stopped the growth of the more treatment-resistant glioblastoma tumor-initiating cells (TICs) as well as non-TICs and impeded tumor initiation and self-renewal of the TIC population. [Sci Transl Med] Abstract

Long Noncoding RNA CUDR Regulates HULC and β-Catenin to Govern Human Liver Stem Cell Malignant Differentiation
The authors provide the first demonstration that CUDR plays a positive potential role in liver cancer stem cell through the cascade of CUDR-HULC/CUDR-β-catenin signaling, and offer insights into a novel link between lncRNA and the epigenetic modification in cancer stem cells. [Mol Ther] Abstract

Carbon Ion Beam Combined with Cisplatin Effectively Disrupts Triple Negative Breast Cancer Stem-Like Cells In Vitro
Human breast cancer stem-like cells sorted from MDA-MB-231 and MDA-MB-453 cells were treated with a carbon ion beam or X-ray irradiation alone or in combination with cisplatin, and then colony, spheroid and tumor formation assays, RT-PCR Array analysis, and immunofluorescence γH2AX foci assay were performed. [Mol Cancer] Full Article

Osteosarcoma Stem Cells Have Active Wnt/β-Catenin and Overexpress SOX2 and KLF4
Investigators showed that different cancer stem cell populations may co-exist in osteosarcoma cell lines exhibiting distinct functional properties. Osteosarcoma spheres are slowly-proliferating populations, overexpress SOX2 and KLF4 stemness-related genes and have enhanced tumorigenic potential. [J Cell Physiol] Abstract

A Quantitative Proteomics Analysis of MCF7 Breast Cancer Stem and Progenitor Cell Populations
Researchers used cancer stem cell (CSC) markers to isolate pure breast CSCs fractions and the mature luminal cells from the MCF7 cell line. Proteomic analysis was performed on these samples and a total of 3,304 proteins were identified. [Proteomics] Abstract

PKCδ Inhibition Impairs Mammary Cancer Proliferative Capacity but Selects Cancer Stem Cells, Involving Autophagy
The authors focused on how protein kinase C (PKC)δ regulates proliferation and cancer stem cell properties of the hormone-independent mammary cancer cell line LM38-LP, using pharmacological and genetic approaches. They found that pharmacological inhibition of PKCδ, by Rottlerin treatment, impairs in vitro LM38-LP proliferation through cell cycle arrest, inducing the formation of cytoplasmic-vacuoles. [J Cell Biochem] Abstract

Lentivirus-Mediated shRNA Targeting Nanog Inhibits Cell Proliferation and Attenuates Cancer Stem Cell Activities in Breast Cancer
Scientists report that Nanog was highly expressed in cancer stem cell-enriched population from breast cancer cells, as well as stemness-associated genes. They found that targeted inhibition of Nanog could suppress proliferation and colony formation in breast cancer cells. [J Drug Target] Abstract

Protocol and Data: Serum-Free, 3D Suspension Assay for Breast Cancer Cells
 
REVIEWS
The Metabolic Landscape of Cancer Stem Cells
The authors summarize the most significant discoveries on the metabolism of cancer stem cells (CSCs), describing and critically analyzing the studies supporting either glycolysis or mitochondrial oxidative phosphorylation as a primary source of energy for CSCs. [IUBMB Life] Abstract

NF-κB Signaling in Cancer Stem Cells: A Promising Therapeutic Target?
The nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathway, which has been found to be constitutively activated in cancer stem cells (CSCs) from a variety of cancers, participates in the maintenance, expansion, proliferation and survival of CSCs. Targeted disruption of this pathway may profoundly impair the adverse phenotype of CSCs and may provide a therapeutic opportunity to remove the CSC fraction. [Cell Oncol] Abstract

Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.
 
INDUSTRY NEWS
Seattle Genetics Completes Enrollment in Phase III ALCANZA Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in CD30-Expressing Cutaneous T-Cell Lymphoma (CTCL)
Seattle Genetics, Inc. announced that the company and its collaborator, Takeda Pharmaceutical Company Limited, completed patient enrollment in the Phase III ALCANZA clinical trial. ALCANZA is a randomized trial evaluating ADCETRIS versus investigator’s choice of methotrexate or bexarotene in 132 patients with CD30-expressing CTCL who received prior systemic therapy. [Seattle Genetics, Inc.] Press Release

U.S. FDA Grants Priority Review to Takeda’s Ixazomib for Patients with Relapsed/Refractory Multiple Myeloma
Takeda Pharmaceutical Company Limited announced that the U.S. Food and Drug Administration (FDA) has granted priority review status to the New Drug Application for ixazomib, the first investigational oral proteasome inhibitor for the treatment of patients with relapsed and/or refractory multiple myeloma. [Takeda Pharmaceutical Company Limited] Press Release

From our sponsor: Induce neural progenitor cells faster and more effectively. Watch the technical video.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW European Molecular Biology Laboratory (EMBL) Conference: Cancer Genomics
November 1-4, 2015
Heidelberg, Germany

Visit our events page to see a complete list of events in the cancer stem cell community.
 
JOB OPPORTUNITIES
NEW Postdoctoral Research Associate – Breast Cancer Invasion / Extracellular Matrix / Proteomics / Microscopy (University of Liverpool)

Postdoctoral Fellowship – Cancer Biology (Mass General Cancer Center/Harvard Medical School)

Postdoctoral Position – Immunology/Vascular Biology/Oncology (University of Toulouse)

Postdoctoral Fellow – Mammalian Stem Cell Model System (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellow – Cancer Biology (National Cancer Institute)

Postdoctoral Research Fellow – Development and Pathogenesis of Pancreatic Cancer (University College London)

Postdoctoral Research Fellow – Cancer Research (Fred Hutchinson Cancer Research Center)

Postdoctoral Positions- Cancer Research (Rutgers University)


Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Cancer Stem Cell News: Archives | Events | Contact Us